Justification and Approval.pdf

PDF 915 KB Posted

Attached to
Reagent Production Capacity Expansion Federal contract opportunity
Solicitation number
75A50223C00009
Issued by
Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response

About this file

This document contains a Justification and Approval for other than full and open competition related to a federal contract opportunity. The justification document outlines a requirement by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to award a sole source contract to Anatrace Products, LLC for $9,591,300 to increase Guanidinium Thiocyanate production capacity by five-hundred-fold. Guanidinium Thiocyanate is a chemical compound used in extracting and isolating viral RNA from SARS-CoV-2 specimens to support COVID-19 testing and analysis. The justification cites authority under FAR 6.302-3 to award to a particular source to maintain an industrial mobilization capability and train a supplier in furnishing critical supplies. The related federal contract opportunity notice shows Contract 75A50223C00009 was awarded to Anatrace Products, LLC on December 23, 2022 for $9,591,300 to meet the Reagent Production Capacity Expansion requirements.

View the file

On GovTribe

Work with this file on GovTribe

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

JUSTIFICATION AND APPROVAL

FOR OTHER THAN FULL AND OPEN COMPETITION

Completion Instructions: The Department of Health and Human Services (HHS) has established a standard template for the preparation of a J&A for Other Than Full and Open Competition. If this is an 8(a) set-aside, please note this form is not required unless the acquisition is valued (including all options) at greater than $22 million. This template is NOT applicable for actions using simplified acquisition procedures (FAR Part 13), Federal Supply Schedule orders (FAR 8.4) or task or delivery orders subject to fair opportunity (FAR 16.505).

Tailor all aspects of this template to the individual acquisition. Consult FAR Subpart 6.3 for guidance. An addendum may be added in case additional space is needed.

When this document is printed, the blue italic instructions are automatically deleted on the printed version.

Acquisition Title:

Agency:

Acquisition Year (FY):

Author and Title:

2. Description of Action:

Nature: New Requirement Follow-on Requirement

Modification to Existing Purchase Order/Contract Number:

Pricing: Firm-Fixed Price Time & Materials Cost

Other:

Funds: OMA Other Funds:

Name of Proposed Contractor(s):

Street Address:

City, State, Zip:

3. Description of Services or Supplies:

Basis for Approval (FAR 6.303-1(d)): Individual Basis Class Basis

The total estimated value of the proposed action, including all options is $

As applicable, briefly describe the services or supplies required to meet the agency's needs, including make & model number where appropriate. Include quantities of supplies or period of performance for services. Provide information for any options included. If the action is a modification to an existing contract, distinguish clearly between the work covered by the original contract and the work to be obtained by the proposed modification.

https://www.acquisition.gov/far/part-8#FAR_Subpart_8_4 https://www.acquisition.gov/far/part-13 https://www.acquisition.gov/far/part-16#FAR_16_505 https://www.acquisition.gov/far/part-6#FAR_Subpart_6_3 https://www.acquisition.gov/far/part-6#FAR_6_303_1

4. Authority and Rationale: Identify the statutory authority, FAR title and FAR citation permitting other than full and open competition. It may be one of the following most commonly used citations by the operating divisions of the Department of Health and Human Services (HHS), but other exceptions may apply per FAR Subpart 6.3.

Actions other than simplified acquisition procedures (select only one and provide an explanation):

FAR 6.302-1: Only one responsible source and no other supplies or services will satisfy agency requirements, 41 U.S.C.

3304(a)(1)

Explain why the intended contractor is the only responsible source who can provide the required supplies or s ervices.

Discuss the unique capabilities, expertise, etc. that support the lack of competition/why no other type of supplies or servic es will satisfy agency requirements. Explain factors/unique qualifications such as proprietary data or exclusive licensing rights, if applicable. When competition is limited to items particular to one manufacturer, this justification must explain why the particular brand name, product, or feature is essential to the Government's requirements, and that market research indicates other companies' similar products, or products lacking the particular feature, do not meet, or cannot be modified to meet the agency's needs in accordance with FAR 11.105. If in connection with a follow-on contract for continued development or production of highly specialized equipment, detail the substantial duplication of cost or unacceptable delays.

FAR 6.302-2: Unusual and compelling urgency, 41 U.S.C. 3304(a)(2)

If unusual and compelling urgency is the basis for the justification, explain the chronological events leading up to the requirement and explain why time constraints cannot permit even a limited competition. Describe the detrimental effects/ serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved. Describe impact of required delivery/performance date. Describe the detrimental effects/ serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved and the product or service cannot be provided by the intended sole source contractor. Failure to plan for expiring funds is not a valid reason for citing this exception. May not exceed one year, including all options, unless the head of the agency determines that exceptional circumstances apply.

FAR 6.302-5: Authorized or Required by Statute, 41 U.S.C. 3304(a)(5)

Provide a citation to the statutory authorization and a brief description of its content, or identify the specified source or other agency.

Other (See FAR Subpart 6.3 for additional authority)

Provide the authority and citation to the applicable section of FAR 6.3.

Provide a full explanation to justify use of the exception.

5. Agency Actions to Take or Remove Barriers That Led to Other Than Full and Open Competition (If applicable):

Describe the actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration prior to any subsequent acquisition for the supplies of services is made. If no such actions have been taken, explain why.

https://www.acquisition.gov/far/part-6#FAR_6_302_1 https://www.acquisition.gov/far/part-6#FAR_Subpart_6_3 https://www.acquisition.gov/far/part-11#FAR_11_105 https://www.acquisition.gov/far/part-6#FAR_6_302_2 https://www.acquisition.gov/far/part-6#FAR_6_302_5

6. Bridge Contracts:

For contract extensions or bridge contracts when a competitive follow-on is in the process of being developed, summarize history of current contract and explain the reasons for any delays in the acquisition. Include discussion of the milestones f or the follow-on action; the milestones should be as efficient as possible. Discuss why it would be neither cost effective nor realistic to expect another contractor to perform during the brief interim period; include issues such as start -up costs, phase-in, transfer of GFP, recruitment and staffing, etc. If the action is because of a protest, provide a brief discussion of the protest including the date the protest was filed and the basis of the protest. Explain that the action will provide the minimum quant ity or performance period.

7. Actions to Increase Competition:

Describe efforts made to compete the action, including whether a notice was or will be publicized as required by FAR Subpart

5.2 or which exception under FAR 5.202 applies. If a notice was publicized, discuss the number of written responses to the synopsis and the results of the assessment of the written responses. List sources, if any, that expressed, in writing, an interest in the acquisition. Provide rationale if interested sources were rejected. If applicable, state that no other sources have expressed interest, but all offers received shall be considered. Describe what actions will be taken to increase competition before subsequent acquisition of the supplies or services is required. You may state that an action is a one-time requirement, but if a similar requirement arises, every effort will be made to compete it to the maximum extent possible. If action is sole source because of proprietary data or licensing rights and there will be a continuing need for the requirement, there must be evidence that advanced planning has been initiated to overcome the barriers to competition, or there should be documentation to support an analysis that replacement costs/licensing purchase costs outweigh the benefits of competition. If the action is a contract extension or bridge, explain actions to compete the follow-on. If action is an urgent new requirement and a competitive follow-on is anticipated, explain that efforts are underway to facilitate a full and open competition.

8. Market Research:

Describe the extent of the market research conducted to identify all qualified sources and the results thereof. “Market Research” is defined as those attempts you made to ascertain whether other qualified sources exist, and can include contact with knowledgeable experts regarding similar or duplicate requirements, contact with industry, results of a sources sought synopsis, or draft solicitations. Research of the marketplace may consist of written, electronic (i.e. email) telephonic, or world wide web inquiries. Lack of advanced planning is not an acceptable reason for the lack of market research, but true urgency may necessitate abbreviated market research that is limited to readily available historical and commercial information. If ac tion is a contract extension or bridge contract, describe the market research efforts underway or completed for the follow-on. See FAR 10.002(b)(2).

9. Procurement History:

Purchase order or contract number:

Was action competed? Yes No

If action was not competed, state the cited authority, summarize rationale, and describe the actions that were supposed to be taken to increase competition and the results thereof:

https://www.acquisition.gov/far/part-5#FAR_Subpart_5_2 https://www.acquisition.gov/far/part-5#FAR_Subpart_5_2 https://www.acquisition.gov/far/part-5#FAR_5_202 https://www.acquisition.gov/far/part-10#FAR_10_002

10.Additional Information to support the justification:

If applicable, explain why technical packages or specifications to facilitate competition were not developed or available;

describe actions taken to remedy the situation.

11. Technical / Requirements Certification: By my signature below, I certify that the supporting data included in this

J&A is accurate and complete.

Program Manager

Name:

Position Title:

Email address:

Phone:

Program Manager Supervisor (or one level above Program Manager)

Name:

Position Title:

Email address:

Signature:

Date:

12. Fair and Reasonable Price/Cost Determination: As Contracting Officer, by my signature below, I hereby determine that the anticipated price/cost to the Government for this contract action will be fair and reasonable.

Provide the basis for this determination, e.g., describe techniques to be used to determine fair and reasonable price (FAR Subpart 15.402), such as price analysis, cost analysis, cost realism. Per FAR Subpart 15.403-4(a)(1), the threshold for obtaining cost or pricing data is $750,000.

Name: Phone:

Signature: Date:

13. Contracting Officer's Approval (Required for proposed contract not to exceed $700,000 (value calculated including all options)): I hereby certify that this justification is accurate and complete to the best of my knowledge. I approve this justification subject to availability of funds, and provided that the services and supplies herein described have otherwise been authorized for acquisition.

Name: Phone:

Signature: Date:

https://www.acquisition.gov/far/part-15#FAR_15_402 https://www.acquisition.gov/far/part-15#FAR_15_402 https://www.acquisition.gov/far/part-15#FAR_15_403_4

14. Legal Review:

All J&As greater than $68 million must have a legal review from the General Law Division of the Office of the General Counsel prior to sending it to the Department.

15. OPDIV Competition Advocate Approval (Required for proposed contract over $700,000 but not exceeding $13.5 million (value calculated including all options)):

I have reviewed this justification and find that it adequately supports other than full and open competition.

Name:

Phone:

Signature:

Date:

All J&As greater than $68 million must have a review from the Office of Small & Disadvantaged Business Utilization (OSDBU) prior to sending it to the Department. The OSDBU at their discretion may review any J&A.

16. Office of Small and Disadvantaged Business Utilization Review: (Required for contracts exceeding $68 million (value calculated including all options)):

Concur:

Non-Concur:

17. OPDIV HCA Approval (Required for proposed contract over $13.5 million but not exceeding $68 million (value calculated including all options)):

18. Department Competition Advocate (Required for contracts exceeding $68 million (value calculated including all options)):

Concur:

Non-Concur:

(The below approval paragraph is required if the cumulative contract value, including all options, exceeds $68 million.)

19. HHS Senior Procurement Executive (SPE) Approval:

Based on the foregoing justification, I hereby approve other than full and open competition for the above stated procurement, subject to the availability of funds, and provided that the services herein described have otherwise been authorized for acquisition.

State supplies/services being procured:

State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304:

Modificationto Existing Purchase OrderContract Number:
Other:
Other Funds: Covid-19 Funds
Name: Gustavo Martir
Position Title: Acquisition Program Manager
Email address: gustavo.martir@hhs.gov
Phone: 240-205-9130
Name_2: Matt Humbard
Position Title_2: Domain Lead
Email address_2: matt.humbard@hhs.gov
Date: December 8, 2022
Phone_2: 202-573-2147
Date_2: 12/9/2022
Phone_3: 202-573-2147
Date_3: 12/9/2022
Name_3:
Phone_4:
Date_4:
Name_4:
Phone_5:
Date_5:
Name_5:
Phone_6:
Date_6:
Name_6:
Phone_7:
Date_7:
Name_7:
Phone_8:
Date_8:
Text51: Reagent Production Capacity Expansion
Text52: Gustavo Martir- Program Manager
Text53: 2023
Dropdown54: [ASPR]
Check Box55: Yes
Check Box56: Off
Check Box57: Off
Check Box58: Yes
Check Box59: Off
Check Box60: Off
Check Box61: Off
Check Box62: Yes
Text63: Anatrace Products, LLC
Text64: 434 W. Dussel Dr
Text65: Maumee, OH 43537
Check Box66: Yes
Check Box67: Off
Text68: 9,591,300
Text69: Health and Human Services (HHS) COVID-19 response priorities, ASPR has a requirement for five-hundred-fold increase in Guanidinium Thiocyanate (GTC) production capacity. GTC is a chemical compound widely used in the extraction and isolation of viral RNA from SARS-CoV-2 specimens needed to support testing and analysis. By bolstering Anatrace's industrial capacity to produce the reagent, production of COVID -19 diagnostic testing will increase to meet the demand for testing. Failure to increase capacity will result in insufficient testing required to combat current COVID-19 needs, immediate spikes in demand, and for near and distant future needs.

This requirement is not only the procurement of additional equipment to support the production ramp up but also ancillary services for install and testing. The expected period of performance is date of award through August 2024.

Text70:
Text71:
Check Box72: Off
Check Box73: Off
Check Box74: Off
Check Box75: Yes
Text76:
Text77:

In accordance with FAR 6.302-3 (a)(2)(i) and (b)(1)(i) Industrial Mobilization - (2)Full and open competition need not be provided for when it is necessary to award the contract to a particular source or sources in order-

(i) To maintain a facility, producer, manufacturer, or other supplier available for furnishing supplies or services in case of a national emergency or to achieve industrial mobilization;

Use of the authority in paragraph (a)(2)(i) of this section may be appropriate when it is necessary to-

(i) Keep vital facilities or suppliers in business or make them available in the event of a national emergency;

(ii) Train a selected supplier in the furnishing of critical supplies or services Text78: The Government is significantly increasing the U.S. access to COVID-19 Screening and Diagnostics testing capability which is critical to getting Americans back to work safely and respond to future outbreaks. Given the challenge of the effort at hand and its importance to the health and livelihoods of the American people, solutions from the test manufacturing community to expand the U.S. Industrial Production Capacity of existing COVID-19 Diagnostic testing capability is critical to not only respond to pandemics but also ensure the security of the nation as it relates to test manufacturing.

Anatrace, L.L.C. produces key reagents that are necessary in the extraction isolation of viral RNA from SARS-CoV-2 specimens needed to support testing and analysis. These include Poly(A), GTC, and Proteinase K, among others. Supply chain limitations of reagents (e.g., RNA extraction kits, buffers, etc.), were one of the factors negatively impacting laboratories providing SARS-Cov-2 testing.

Text79: The initial acquisition was competed by Department of Defense using Commercial Solutions Opening Pilot Program (CSO). Anatrace Products LLC was one of 17 vendors that was invited to propose, and they were awarded IDIQ FA8734-21-D-0001 by the Air Force. The action was then transfered to HHS to complete the work. HHS however does not have CSO authority and cannot transfer the IDIQ contract. In order to meet the needs of the Government and to obtain full benefit of the work already completed and funded by the Government, this sole source award to Anatrace is needed for Anatrace to complete the initiated work.

DoD followed competition procedures in accordance with the CSO pilot program. CSO promotes competition with a streamlined approach to address specific needs for innovative commercial items which included acquisition planning and conducting market research. This pilot program offers a range of advantages to open up the field of competition so that the Government and taxpayers benefit from a large pool of solutions at a better cost and performance.

If there is a future need for this requirement, a new competitive contract will be pursued.

Text80: N/A
Text81: The initial acquisition was competed by DoD using Commercial Solutions Opening Pilot Program (CSO). Anatrace Products LLC was one of 17 vendors that was invited to propose, and they were awarded IDIQ FA8734-21-D-0001 by the Air Force. The action was then transfered to HHS to complete the work. HHS however does not have CSO authority and cannot transfer the IDIQ contract. In order to meet the needs of the Government and to obtain full benefit of the work already completed and funded by the Government, Anatrace needs about 24 months to complete the initiated work. HHS must issue a directed sole source contract to Anatrace Products LLC to meet the Government's needs.

The Government has already invested $1,462,490 to increase the production of GTC, this contract would allow for further expansion and production. A new competition would lead to loss of time and investment and set the government back from achieving the required increased production capacity. Failure to increase capacity will result in insufficient testing required to combat current COVID-19 needs, as well as immediate spikes in demand, and for near and distant future needs.

If there is a future need for this requirement, a new competitive contract will be pursued.

Check Box82: Yes
Check Box83: Off
Text84: We are awarding a directed Sole Source to the vendor, Anatrace, as HHS is not able to transfer the executed IDIQ contract from the Air Force to complete the 2nd task order. Additionally, HHS does not have Commercial Solutions Opening Pilot Program (CSO) authority to execute the transfer of the IDIQ contract and subsequent task orders. This sole source will continue the work started by the vendor on the first task order awarded by DoD on behalf of HHS through the CSO authority.

DoD followed competition procedures in accordance with the CSO pilot program. CSO promotes competition with a streamlined approach to address specific needs for innovative commercial items which included acquisition planning and conducting market research. This pilot program offers a range of advantages to open up the field of competition so that the Government and taxpayers benefit from a large pool of solutions at a better cost and performance. Antrace was 1 of 77 proposals submitted in support of the Screening and Diagnostics Areas of Interest (AoI). After further evaluation, Anatrace was 1 of 17 proposals invited to submit a Spiral 2 proposal and participate in Oral Presentations.

Text85: FA8734-21-D-0001
Text86:
Text87: HHS does not have CSO authority to execute this award. HHS has to award a sole source to Anatrace Products LLC in order to meet the needs of the Government. This will allow the Contractor to complete the work that they already started while working under the IDIQ which was awarded through the CSO by DoD.

The initial acquisition was competed by DoD using Commercial Solutions Opening Pilot Program (CSO). Anatrace Products LLC was one of 17 vendors that was invited to propose, and they were awarded IDIQ FA8734-21-D-0001 by the Air Force. This action and completion of Anatrace's work is being transfered to HHS. HHS however does not have CSO authority and cannot transfer the IDIQ contract.

The Government has already invested $1,462,490 to increase the production of GTC, this sole source contract would allow for further expansion and production. A new competition would lead to loss of time and investment and set the government back from achieving the increased capacity. Failure to increase capacity will result in insufficient testing required to combat current COVID-19 needs, as well as immediate spikes in demand, and for near and distant future needs.

2022-12-08T12:55:24-0500
Matthew A. Humbard -S
Text89: Judy Williams
Text90: Judy Williams
2022-12-09T11:32:07-0500
Judy O. Williams -S
2022-12-09T12:09:38-0500
Judy O. Williams -S
Text93:
Check Box96: Off
Check Box97: Off
Check Box98: Off
Check Box99: Off
Text102:
Text103:
Text105: The contracting officer will perform price analysis evaluation to determine fair and reasonableness. The price analysis may include the following:

i. Comparison of proposed prices with the Independent Government Cost Estimates (IGCE) iii Comparison of previously proposed prices and previous Government and commercial contract prices with current proposed prices for like items

iii. Comparison of proposed prices with prices obtained through market research for the same or similar items (i.e. GSA Advantage, and VA Prime vendor Program)

iv. Information obtained from market research that was conducted prior Text1:

File details come from the government source that posted it. Updated .